Orosomucoid in Urine is a Powerful Predictor of Cardiovascular Mortality in Normoalbuminuric Patients with Type 2 Diabetes at Five Years of Follow-up

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2005 Jan 13

PMID 15645208

Citations 12

Authors

M S Christiansen

E Hommel

E Magid

B Feldt-Rasmussen

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: To study whether urinary orosomucoid excretion rate (UOER) predicts mortality in normoalbuminuric patients with diabetes at 5 years of follow-up, and to investigate the relationship between orosomucoid in serum and urine.

Methods: A cohort of 578 patients with diabetes (430 type 2, 148 type 1) was followed prospectively for an average of 5 years. UOER was measured in timed overnight urine samples.

Results: Eighty-two patients with type 2 diabetes and 17 patients with type 1 diabetes died. Among patients with type 2 diabetes, 251 (58%) had normoalbuminuria; increased UOER independently predicted cardiovascular mortality (OR 4.94, 95% CI 1.60-15.22; p<0.006) in those with normoalbuminuria and in the entire cohort of patients with type 2 diabetes (odds ratio 3.63, 95% CI 1.50-8.81; p<0.005). Patients with increased UOER had a higher all-cause mortality than those with normal UOER (log-rank test, p<0.001 for type 2 patients; p<0.04 for type 1 patients). In patients with type 1 diabetes, there were five cardiovascular deaths and no significant predictive value of UOER. Patients with increased UOER had a subclinical increase in serum orosomucoid.

Conclusion/interpretation: Increased UOER was an independent, powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes and in the entire cohort of patients with type 2 diabetes. There were indications of UOER as being a valuable marker in type 1 diabetes that showed differences in survival between patients with normal versus increased UOER. Serum orosomucoid was associated with UOER; UOER may be a marker of low-grade inflammation in patients with diabetes.

Citing Articles

Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis.

Ahmad A, Lim L, Morieri M, Tam C, Cheng F, Chikowore T Commun Med (Lond). 2024; 4(1):11.

PMID: 38253823 PMC: 10803333. DOI: 10.1038/s43856-023-00429-z.

New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease.

Weng Q, Zhou Q, Tong J, Jin Y, Liu Y, Yu X Clin Proteomics. 2020; 17:18.

PMID: 32514258 PMC: 7257237. DOI: 10.1186/s12014-020-09282-x.

A point-of-care assay for alpha-1-acid glycoprotein as a diagnostic tool for rapid, mobile-based determination of inflammation.

Gannon B, Glesby M, Finkelstein J, Raj T, Erickson D, Mehta S Curr Res Biotechnol. 2020; 1:41-48.

PMID: 32342042 PMC: 7185229. DOI: 10.1016/j.crbiot.2019.09.002.

Hypoxia is not the primary mechanism contributing to exercise-induced proteinuria.

Joyce K, Delamere J, Bradwell S, Myers S, Ashdown K, Rue C BMJ Open Sport Exerc Med. 2020; 6(1):e000662.

PMID: 32341794 PMC: 7173992. DOI: 10.1136/bmjsem-2019-000662.

Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.

Youngblood H, Robinson R, Sharma A, Sharma S Int J Mol Sci. 2019; 20(19).

PMID: 31557880 PMC: 6801709. DOI: 10.3390/ijms20194755.

References

Vasson M, BAGUET J, Arveiller M, Bargnoux P, Giroud J, Raichvarg D . Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron. 1993; 65(2):299-303. DOI: 10.1159/000187492. View

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

Schmitz A, Vaeth M . Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med. 1988; 5(2):126-34. DOI: 10.1111/j.1464-5491.1988.tb00958.x. View

Christiansen M, Blirup-Jensen S, Foged L, Larsen M, Magid E . A particle-enhanced turbidimetric immunoassay for quantitative determination of orosomucoid in urine: development, validation and reference values. Clin Chem Lab Med. 2004; 42(10):1168-77. DOI: 10.1515/CCLM.2004.237. View

Laing S, Swerdlow A, Slater S, Burden A, Morris A, Waugh N . Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003; 46(6):760-5. DOI: 10.1007/s00125-003-1116-6. View

Schalkwijk C, Poland D, van Dijk W, Kok A, Emeis J, Drager A . Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42(3):351-7. DOI: 10.1007/s001250051162. View

Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J . A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993; 16(7):996-1003. DOI: 10.2337/diacare.16.7.996. View

Harvey J, Rizvi K, Craney L, Messenger J, Shah R, Meadows P . Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabet Med. 2002; 18(12):998-1002. DOI: 10.1046/j.1464-5491.2001.00630.x. View

Allen K, Walker J . Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 2003; 26(8):2389-91. DOI: 10.2337/diacare.26.8.2389. View

10.

McMillan D . Increased levels of acute-phase serum proteins in diabetes. Metabolism. 1989; 38(11):1042-6. DOI: 10.1016/0026-0495(89)90038-3. View

11.

Rossing P, Hougaard P, Borch-Johnsen K, Parving H . Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996; 313(7060):779-84. PMC: 2352213. DOI: 10.1136/bmj.313.7060.779. View

12.

Schmid K . Human plasma alpha 1-acid glycoprotein--biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism. Prog Clin Biol Res. 1989; 300:7-22. View

13.

Christiansen M, Hommel E, Magid E, Feldt-Rasmussen B . Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. Diabetologia. 2002; 45(1):115-20. DOI: 10.1007/s125-002-8251-3. View

14.

Mogensen C, Keane W, BENNETT P, Jerums G, Parving H, Passa P . Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995; 346(8982):1080-4. DOI: 10.1016/s0140-6736(95)91747-0. View

15.

Mogensen C . Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310(6):356-60. DOI: 10.1056/NEJM198402093100605. View

16.

Roper N, Bilous R, Kelly W, Unwin N, Connolly V . Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care. 2002; 25(1):43-8. DOI: 10.2337/diacare.25.1.43. View

17.

Gall M, Borch-Johnsen K, Hougaard P, Nielsen F, Parving H . Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995; 44(11):1303-9. DOI: 10.2337/diab.44.11.1303. View

18.

Ito S, Tsuda A, Momotsu T, Igarashi K, Kasahara S, Satoh K . Urinary orosomucoid excretion rate in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh). 1989; 120(5):584-90. DOI: 10.1530/acta.0.1200584. View

19.

Hillege H, Fidler V, Diercks G, van Gilst W, de Zeeuw D, Van Veldhuisen D . Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106(14):1777-82. DOI: 10.1161/01.cir.0000031732.78052.81. View

20.

Morrish N, Wang S, Stevens L, Fuller J, Keen H . Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 Suppl 2:S14-21. DOI: 10.1007/pl00002934. View